The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
Open accessAbstract
OBJECTIVE: To assess the efficacy and safety of favipiravir in adults with mild-to-moderate coronavirus disease 2019 (COVID-19). METHODS: In this randomized, open-label, parallel-arm, multicenter, phase 3 trial, adults (18-75 years) with RT-PCR confirmed COVID-19 and mild-to-moderate symptoms (including asymptomatic) were randomized 1:1 to oral favipiravir (day 1: 1800 mg BID and days 2-14: 800 mg BID) plus standard supportive care versus supportive care alone. The primary endpoint was time to the cessation of viral shedding; time to clinical cure was also measured. RESULTS: From May 14 to July 3, 2020, 150 patients were randomized to favipiravir (n = 75) or control (n = 75). Median time to the cessation of viral shedding was 5 days (95% CI: 4 days, 7 days) versus 7 days (95% CI: 5 days, 8 days), P = 0.129, and median time to clinical cure was 3 days (95% CI: 3 days, 4 days) versus 5 days (95% CI: 4 days, 6 days), P = 0.030, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients. One control patient died due to worsening disease. CONCLUSION: The lack of statistical significance on the primary endpoint was confounded by limitations of the RT-PCR assay. Significant improvement in time to clinical cure suggests favipiravir may be beneficial in mild-to-moderate COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., et al. (2020) · Engineering · doi:10.1016/j.eng.2020.03.007 · Cited by 1,357
RetractedA pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,347
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Dong, L., Hu, S., & Gao, J. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.01012 · Cited by 1,390
Spinner, C. D., Gottlieb, R. L., Criner, G. J., Arribas López, J. R., Cattelan, A. M., Soriano Viladomiu, A., Ogbuagu, O., Malhotra, P., Mullane, K. M., Castagna, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.16349 · Cited by 1,211
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.015 · Cited by 1,072
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2020) · doi:10.1101/2020.03.17.20037432 · Cited by 852
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.683296 · Cited by 849
Xu, K., Chen, Y., Yuan, J., Yi, P., Ding, C., Wu, W., Li, Y., Ni, Q., Zou, R., Li, X., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa351 · Cited by 501
Self-citationFavipiravir: A new and emerging antiviral option in COVID-19
Agrawal, U., Raju, R., & Udwadia, Z. F. (2020) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2020.08.004 · Cited by 390
Self-citationFavipiravir as a potential countermeasure against neglected and emerging RNA viruses
Delang, L., Abdelnabi, R., & Neyts, J. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.03.003 · Cited by 388
A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
Pilkington, V., Pepperrell, T., & Hill, A. (2020) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30016-9 · Cited by 271
Ivashchenko, A. A., Dmitriev, K. A., Vostokova, N. V., Azarova, V. N., Blinow, A. A., Egorova, A. N., Gordeev, I. G., Ilin, A. P., Karapetian, R. N., Kravchenko, D. V., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1176 · Cited by 255
Doi, Y., Hibino, M., Hase, R., Yamamoto, M., Kasamatsu, Y., Hirose, M., Mutoh, Y., Homma, Y., Terada, M., Ogawa, T., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01897-20 · Cited by 223
Song, Y., Zhang, M., Yin, L., Wang, K., Zhou, Y., Zhou, M., & Lu, Y. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106080 · Cited by 204
SARS-CoV-2: The viral shedding vs infectivity dilemma
Widders, A., Broom, A., & Broom, J. (2020) · Infection, Disease & Health · doi:10.1016/j.idh.2020.05.002 · Cited by 189
Goyal, A., Cardozo-Ojeda, E. F., & Schiffer, J. T. (2020) · Science Advances · doi:10.1126/sciadv.abc7112 · Cited by 189
Qi, L., Yang, Y., Jiang, D., Tu, C., Wan, L., Chen, X., & Li, Z. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.05.045 · Cited by 146
Heneghan, C. J., Onakpoya, I., Jones, M., Doshi, P., Mar, C. D., Hama, R., Thompson, M., Spencer, E. A., Mahtani, K. R., Nunan, D., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20420 · Cited by 111
Clearance and persistence of SARS‐CoV‐2 RNA in patients with COVID‐19
do Carmo, A., Pereira‐Vaz, J., Mota, V., Mendes, A., Morais, C., da Silva, A. C., Camilo, E., Pinto, C. S., Cunha, E., Pereira, J., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26103 · Cited by 103
SARS-CoV-2 RNA polymerase as target for antiviral therapy
Buonaguro, L., Tagliamonte, M., Tornesello, M. L., & Buonaguro, L. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02355-3 · Cited by 83
Risk factors for viral RNA shedding in COVID-19 patients
Fu, Y., Han, P., Zhu, R., Bai, T., Yi, J., Zhao, X., Tao, M., Quan, R., Chen, C., Zhang, Y. W., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01190-2020 · Cited by 83
Regulatory requirements for clinical trials in India: What academicians need to know
Gogtay, N., Ravi, R., & Thatte, U. M. (2017) · Indian Journal of Anaesthesia · doi:10.4103/ija.ija_143_17 · Cited by 67
An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2
Schiffer, J. T., Johnston, C., Wald, A., & Corey, L. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa232 · Cited by 18
Cited by
Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
Hassanipour, S., Arab-Zozani, M., Amani, B., Heidarzad, F., Fathalipour, M., & Martinez-de-Hoyo, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-90551-6 · Cited by 264
Metadata
- Authors
- Udwadia, Z. F., Singh, P., Barkate, H., Patil, S., Rangwala, S., Pendse, A., Kadam, J., Wu, W., Caracta, C. F., & Tandon, M.
- Venue
- International Journal of Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 103
- Pages
- 62-71
- ISSN
- 1201-9712 (ISSN-L)
- OpenAlex
- W3098266159
- Cited by
- 282
- References
- 26
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.